Surrogate Markers of Neutrophil Extracellular Trap Formation are Associated with Ischemic Outcomes and Platelet Activation after Peripheral Angioplasty and Stenting

• Main Authors: Svitlana Demyanets, Stefan Stojkovic, Lisa-Marie Mauracher, Christoph W. Kopp, Johann Wojta, Johannes Thaler, Simon Panzer, Thomas Gremmel
• Format: Article
• Language: English
• Published: MDPI AG 2020-01-01
• Series: Journal of Clinical Medicine
• Subjects: peripheral artery disease; citrullinated histone h3; cell-free dna; outcome; platelet reactivity
• Online Access: https://www.mdpi.com/2077-0383/9/2/304

Neutrophil extracellular traps (NETs) are supposed to play a central role in atherothrombosis. We measured circulating citrullinated histone H3 (H3Cit) and cell-free DNA (cfDNA), which serve as surrogate markers of NET formation, in 79 patients with peripheral artery disease (PAD) following infrainguinal angioplasty with stent implantation. Analysis of cfDNA and H3Cit was performed using Quant-iT&#8482; PicoGreen^&#174; dsDNA Assay Kit or an ELISA, respectively. Within two years of follow-up, the primary endpoint defined as nonfatal myocardial infarction, stroke or transient ischemic attack, cardiovascular death, and &gt;80% target vessel restenosis occurred in 34 patients (43%). Both H3Cit (HR per 1-SD: 2.72; 95% CI: 1.2&#8722;6.3; <i>p</i> = 0.019) and cfDNA (HR per 1-SD: 2.15; 95% CI: 1.1&#8722;4.2; <i>p</i> = 0.028) were associated with the primary endpoint in a univariate Cox regression analysis. Multivariate linear regression analyses showed associations between cfDNA and platelet surface expression of P-selectin (<i>p</i> = 0.006) and activated glycoprotein IIb/IIIa (<i>p</i> &lt; 0.001) in response to arachidonic acid (AA) after adjustment for age, sex, clinical risk factors, and inflammatory markers. H3Cit was also associated with P-selectin expression in response to thrombin-receptor activating peptide (<i>p</i> = 0.048) and AA (<i>p</i> = 0.032). Circulating H3Cit and cfDNA predict ischemic outcomes after peripheral angioplasty with stent implantation, and are associated with on-treatment platelet activation in stable PAD.